PHARM2FARM
11.3.2021 10:32:12 CET | Business Wire | Press release
A new anti-viral mask which kills 99.9% of Covid-19 virus within five minutes of contact has been launched today – offering an unparalleled level of protection against viruses not just for those around them but for the wearer too.
Aimed at all types of industry, from hospital and care homes, to schools, to the retail & leisure industries, Pro-Larva differs from conventional masks because, as well as protecting those around the wearer, it protects the wearer themselves, using revolutionary copper nanoparticle technology developed here in the UK.
Antony Legge, Chairman of the parent company Pharm2Farm explains: “Conventional surgical-type TR2 masks only block virus from exiting the mask – they don’t have an active mechanism for killing it once it’s trapped in the mask. Pro-Larva has been designed to use existing barrier technology but also to combine it with α-virion™, a copper nanoparticle technology that kills 99.9% of the virus once it is trapped in the mask.”
This viricidal layer is effective for up to seven hours. Current surgical masks are only effective for around two hours, which requires health care professionals in Intensive Care Units (ICUs) to wear between 4-10 masks per day.
Because of Pro-Larva’s longer effective life this greatly reduces the number of masks required, therefore reducing costs for the hospital or care home. Pro-Larva is also self-sterilising – killing Covid-19 on contact means there is no infection risk from discarded masks after use, removing any potential biohazard.
The effectiveness of the mask against the coronavirus and Influenza has been tested by an independent laboratory and a leading UK university. It has also received European regulatory approval and carries a CE mark, meaning it has been independently reviewed.
The Pro-Larva idea was developed by scientists at Pharm2Farm led by Dr Gareth Cave. Pharm2Farm recently installed a face mask production line in Nottingham, UK and are working with European and global face mask manufacturers to scale-up the supply of Pro-Larva to meet demand.
Dr Gareth Cave, founder of the technology and Pharm2Farm, added: “Helping healthcare professionals protect themselves, their co-workers and patients is very important, and we are keen to support the NHS. However, there are many other categories of frontline workers we are looking to engage with – from schools to care home workers, to the retail and leisure industries – who could benefit from this next generation mask.”
-Ends-
Notes to Editors
About Pharm2Farm
Pharm2Farm is a VC backed Nottingham Trent University spin-out which provides advanced nanoparticle-based solutions for plant, animal and human care through a patented novel production process. For more information, please visit the website: www.pharm2farm.org
About the Pro-Larva mask
The 4 ply anti-viral disposable medical mask from Pharm2Farm Ltd is proven to kill up to 99.9% of coronaviruses and 90% of influenza for up to 7 hours. The mask is splash resistant with a melt blown filter and hypoallergenic layers and uses Pharm2Farm’s proprietary α-virion™ virucidal technology, featuring copper nanoparticles. The Pro-Larva mask is CE marked and its α-virion™ layer has been certified to ISO 18184 standards. ISO 18184 is a standard protocol to quantify the antiviral properties of textile materials. For more information about Pro-Larva mask, its features and suppliers, please visit: https://pro-larva.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005101/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sinopec Receives CSR Award at Sino-European ESG Conference in Germany1.7.2026 15:38:00 CEST | Press release
China Petroleum & Chemical Corp. (Sinopec) has received the Corporate Social Responsibility Best Practice Award at the 3rd Sino-European Corporate ESG Best Practice Conference in Mainz, Germany, for its case study on carbon footprint management and low-carbon development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701696760/en/ Huang Yiyang (L), Chinese Consul General in Frankfurt, presents the award to a representative of Sinopec. The conference jury said Sinopec has developed a carbon management framework centered on product carbon footprint management, covering the full product life cycle while aligning with both Chinese and European standards. It cited the company’s work with German chemical producer BASF to achieve mutual recognition of carbon footprint accounting methodologies as a milestone that could support greener cooperation across international industrial supply chains. According to the jury, Sinopec’s eff
Vercel and Mercedes-AMG PETRONAS Formula One Team Announce Multi-Year Strategic Partnership1.7.2026 15:30:00 CEST | Press release
The agentic infrastructure platform known for speed is joining forces with one of the world's fastest Formula One teams Today Vercel, the agentic infrastructure company, announced a new multi-year deal with the Mercedes-AMG PETRONAS Formula One Team. Starting with the British Grand Prix July 2 – 5 2026, Vercel branding will appear on the Mercedes-AMG PETRONAS Formula One Team race cars as the partnership begins its first chapter, before expanding significantly across the team ecosystem from 2027 onward. The partnership includes global branding rights, premium hospitality experiences, customer engagement, content creation, and technical collaborations, including plans to evolve the team’s digital platforms to Vercel. “Formula One is where every millisecond matters, every decision counts, and continuous innovation is fundamental to success. Vercel shares that same philosophy,” said Richard Sanders, Chief Commercial Officer, Mercedes-AMG PETRONAS Formula One Team. “The Vercel platform is
OXMIQ Raises $35 Million to Scale OxCore™ Architecture1.7.2026 15:15:00 CEST | Press release
OXMIQ Labs Inc., a unified GPU and AI architecture company founded by Raja Koduri, today closed its $35 million Series A financing, bringing the company’s total capital raised to $60 million. The funding will scale OxCore™, OXMIQ’s licensable GPU architecture that allows semiconductor companies and AI system builders to build custom AI silicon without a full chip program. The round was co-led by Fundomo and Samsung Catalyst Fund, with participation from MediaTek, AM Intelligence Labs, Pegatron Venture Capital, CDIB-TEN, Darwin Ventures, and Morgan Creek Digital, among other financial and strategic investors. OXMIQ’s expertise spans the full AI stack, from renewable power and data center infrastructure to silicon IP, electron-to-token machines (ETMs™), along with the software that runs AI factories and agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701241910/en/ OXMIQ Funding raised to date of $60M after current $3
SamanTree Medical’s Histolog® Scanner Technology Featured in 13 Publications in Special BJU International Issue on Confocal Microscopy in Urology1.7.2026 15:01:00 CEST | Press release
Papers highlight clinical research on use of confocal microscopy for real-time tissue assessment in various urologic procedures SamanTree Medical, a global leader in surgical imaging innovation, today announced that Histolog Scanner confocal microscopy technology has been featured in 13 peer-reviewed clinical papers in a special issue of BJU International, one of the world’s leading journals in urology. The special edition focuses on a growing body of evidence of the role of confocal microscopy in urologic surgery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701425845/en/ SamanTree Medical announces that Histolog® Scanner confocal microscopy technology is featured in 13 peer-reviewed clinical papers in a special issue of BJU International. “The special issue represents increasing momentum behind confocal microscopy in urologic surgery,” said Professor Greg Shaw, consultant urologic surgeon at University College London
Regnology to Acquire Fed Reporter, Accelerating U.S. Leadership and Advancing Regulatory Modernization1.7.2026 15:00:00 CEST | Press release
Deal establishes Regnology as a central partner in U.S. regulatory modernization, extending reach to over 4,000 financial institutions Regnology, a leading provider at the intersection of regulatory, risk, and supervisory technology, today announced it has entered into a definitive agreement to acquire Fed Reporter, the market-leading U.S. provider of regulatory reporting solutions for financial institutions of all sizes, including banks, credit unions, and bank holding companies. The acquisition marks a pivotal milestone in Regnology’s U.S. expansion, creating the most comprehensive regulatory reporting coverage across the American financial landscape and extending its reach to more than 4,000 institutions from global banks to community lenders. By combining a proven, cloud-first, agentic-first technology foundation with deeply embedded local expertise, Regnology is uniquely positioned to support more efficient, transparent, and data-driven reporting, while strengthening alignment bet
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom